Alys Pharmaceuticals has acquired multiple assets from six companies, all focused on specific dermatology indications. The resulting balanced pipeline has been designed to develop cutting-edge modalities to address unmet medical needs and improve the quality of life for patients worldwide.
Alys has identified molecular targets largely validated in its diseases of interest, and pairs APIs from various molecular classes with tissue or cell-subtype vectoring strategies, including covalent conjugation and proprietary delivery methodologies. Each of our advanced modalities is a technology suite specifically designed with the unmet medical needs in mind.
Alys Pharmaceuticals is prosecuting a consolidated pipeline of more than a dozen programs in the fields of immune-inflammatory skin diseases, auto-immune skin diseases and specialty dermatology. Alys intends to have achieved IND filings for all programs, as well as having seven Phase 1B/2 early read-outs completed by Q4 2026.
To stay updated on our journey to bring these innovative treatments to patients globally, see our news page.